Skip to main content
International Journal of Endocrinology logoLink to International Journal of Endocrinology
. 2017 May 30;2017:2846080. doi: 10.1155/2017/2846080

Corrigendum to “Osteoporosis, Fractures, and Diabetes”

Peter Jackuliak 1,*, Juraj Payer 1
PMCID: PMC5476871  PMID: 28676823

In the article titled “Osteoporosis, Fractures, and Diabetes” [1], there was an error regarding the FRAX® tool, which should be clarified as follows:

The article notes: “To partially answer this problem the current osteoporosis classification criteria drafted by the World Health Organization (WHO) are currently revised to include clinical risk factors (http://www.shef.ac.uk/FRAX/)” and “Recently, the fracture risk assessment (FRAX) algorithm has been developed by the WHO, which could assess the fracture risk of an individual even if BMD is not measured [109].” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX® tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.

References

  • 1.Jackuliak P., Payer J. Osteoporosis, fractures, and diabetes. International Journal of Endocrinology. 2014;2014:p. 10. doi: 10.1155/2014/820615.820615 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ford N., Norris S. L., Hill S. R. Clarifying WHO’s position on the FRAX® tool for fracture prediction. Bulletin of the World Health Organization. 2016;94(12):p. 862. doi: 10.2471/BLT.16.188532. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Endocrinology are provided here courtesy of Wiley

RESOURCES